Loading...
•
Dec 31, 2024
Autolus Q4 2024 Earnings Report
Autolus reported its Q4 2024 results, showing a small revenue contribution and continued net loss.
Key Takeaways
Autolus posted a Q4 net loss of $27.6 million with $29,000 in revenue and an EPS of -0.09. The quarter reflected ongoing investments into commercialization and pipeline development ahead of broader regulatory milestones.
Net loss of $27.6 million in Q4
Revenue of $29,000 in the quarter
Strong progress on AUCATZYL® commercial rollout
Solid cash position of $588 million at year-end
Forward Guidance
Autolus projects continued growth with further international approvals and clinical data milestones, supported by a robust financial position.
Positive Outlook
- 33 authorized treatment centers for AUCATZYL® in the U.S.
- EMA and MHRA decisions expected in H2 2025
- Initial SLE Phase 1 data presentation in April 2025
- Strong pipeline development plans in place
- Well-capitalized with $588M in cash and equivalents
Challenges Ahead
- Still early-stage revenue generation
- Sustained operating losses expected in near term
- Heavy R&D and SG&A expenses impacting profitability
- Dependency on timely regulatory approvals
- Competitive pressures in CAR T therapy space
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...